56 citations
,
July 2008 in “European journal of endocrinology” This study found that a 6-month treatment with either metformin or rosiglitazone significantly improved endothelial function in young women with PCOS without any one drug being superior.
40 citations
,
April 2008 in “European journal of endocrinology” In this study, treatment with insulin sensitizers significantly increased adipose tissue GLUT4 mRNA expression and improved insulin resistance, menstrual patterns, and androgen profiles in PCOS patients, with rosiglitazone being more effective than metformin.
19 citations
,
March 2007 in “Journal of diabetes science and technology” This study found that both metformin and rosiglitazone improved ovulation and insulin sensitivity in women with PCOS, with rosiglitazone showing a more pronounced increase in adiponectin levels.
343 citations
,
December 2008 in “Endocrine Reviews” This review discusses the various evidence-based and potential applications of metformin in treating and preventing symptoms and complications associated with polycystic ovary syndrome but reports no new clinical results.
88 citations
,
August 2014 in “PLOS genetics” This study found that mice lacking syndecan-1 experienced cold stress and metabolic issues due to reduced intradermal fat, which was restored by thermoneutral housing or rosiglitazone treatment.